CytomX Therapeutics (STU:6C1) Operating Cash Flow per Share : €-1.10 (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics Operating Cash Flow per Share?

CytomX Therapeutics's operating cash flow per share for the three months ended in Mar. 2024 was €-0.29. CytomX Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.10.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for CytomX Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

During the past 11 years, CytomX Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 71.40% per year. The lowest was -281.10% per year. And the median was 17.20% per year.

STU:6C1's 3-Year OCF Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.35
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

CytomX Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for CytomX Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics Operating Cash Flow per Share Chart

CytomX Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-2.79

0.09

-1.64

-1.59

-0.70

CytomX Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															0.13	-0.35	-0.21	-0.25	-0.29

Competitive Comparison of CytomX Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, CytomX Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytomX Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Price-to-Operating-Cash-Flow falls into.

CytomX Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

CytomX Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-51.384	/	73.808
	=	-0.70

CytomX Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-23.961	/	82.630
	=	-0.29

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.10

CytomX Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics (STU:6C1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

CTMX:USA 6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics (STU:6C1) Headlines

No Headlines